Investors
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.
With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include potentially differentiated product candidates against validated targets.
Press Releases
February 6, 2023
December 30, 2022
December 19, 2022
FRONT >> News > View All
Latest Events
January 9, 2023
November 29, 2022 at 9:00 AM EST
October 4, 2022 at 8:30 AM EDT
FRONT > Events - View All
Stock Quote
- Change
- Volume
- Today's Open
- Previous Close
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FRONT >> Stock > View All
Email Alerts
Investor Contact
Ina McGuinness
Tel: +1 (212) 867-1768
imcguinness@connectpharm.com